3-D Matrix, Ltd. (DMTRF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
3-D Matrix, Ltd. (DMTRF) trades at $2.50 with AI Score 66/100 (Grade B+). 3-D Matrix, Ltd. specializes in self-assembling peptide technology, developing innovative hydrogels like PuraMatrix. Market cap: $300.53M, Sector: Healthcare.
Price live · AI analysis from Jun 14, 2026Analyst Coverage for DMTRF: DMTRF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates DMTRF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
DMTRF: 3/5 perspectives are bullish. Dominant signal: Seth Klarman bearish.
How is this calculated? →3-D Matrix, Ltd. (DMTRF) Healthcare & Pipeline Overview
3-D Matrix, Ltd. is a Tokyo-based healthcare company, founded in 2004, pioneering self-assembling peptide technology. Its core product, PuraMatrix, is a hydrogel platform utilized across critical medical fields including regenerative medicine, advanced cell therapy, targeted drug delivery, and specialized surgical applications, positioning it within the innovative medical devices sector.
What Is the Investment Thesis for DMTRF?
3-D Matrix, Ltd. presents a unique investment profile driven by its proprietary self-assembling peptide technology and its broad applicability in high-growth medical sectors. The company's PuraMatrix hydrogel platform is a key value driver, addressing critical needs in regenerative medicine, cell therapy, drug delivery, and surgical treatment. Financially, 3-D Matrix demonstrates strong operational efficiency with a Profit Margin of 38.2% and an exceptional Gross Margin of 78.7%, indicating robust pricing power and cost management for its specialized product. An impressive Return on Equity (ROE) of 92.2% further underscores its ability to generate significant profits from shareholder investments. Growth catalysts are anticipated from the continued expansion and adoption of PuraMatrix across its diverse application areas, particularly as advancements in regenerative medicine and cell therapies accelerate. However, investors must consider the company's Debt-to-Equity ratio of 8.83, which suggests a reliance on debt financing, and the inherent risks associated with its OTC market listing, including potential liquidity challenges and disclosure limitations. The company's continued innovation in its core technology and strategic partnerships will be crucial for sustained growth.
Based on FMP financials and quantitative analysis
DMTRF Key Highlights
- Market capitalization stands at $0.48 billion, reflecting its current valuation within the specialized medical devices sector.
- Achieved a robust Profit Margin of 38.2%, indicating strong operational efficiency and profitability derived from its proprietary peptide technology.
- Maintains an impressive Gross Margin of 78.7%, underscoring the high value and cost efficiency associated with its PuraMatrix product.
- Demonstrates an exceptional Return on Equity (ROE) of 92.2%, highlighting efficient utilization of shareholder capital to generate substantial profits.
- Exhibits a Debt-to-Equity ratio of 8.83, suggesting a relatively high reliance on debt financing in its capital structure.
Who Are DMTRF's Competitors?
DMTRF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| DCTH Delcath Systems, Inc. | $13.61 | +3.11% | $469.84M | 73 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.20 | +3.40% | $18.68M | 73 |
| SSII SS Innovations International, Inc. | $3.76 | -0.53% | $752.49M | 72 |
| RSHUF Respiri Limited | $0.06 | +0.00% | $91.52M | 68 |
| BWAY BrainsWay Ltd. | $16.02 | +5.46% | $628.35M | 66 |
| CNVIF Conavi Medical Corp. | $0.18 | +0.00% | $15.36M | 66 |
| PROF Profound Medical Corp. | $7.21 | +5.87% | $218.16M | 67 |
| SENS Senseonics Holdings, Inc. | $5.66 | +3.36% | $236.74M | 67 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are DMTRF's Key Strengths?
- Proprietary self-assembling peptide technology (PuraMatrix) with broad medical applications.
- Strong financial performance metrics including a 38.2% Profit Margin and 78.7% Gross Margin.
- Exceptional Return on Equity (ROE) of 92.2% demonstrating efficient capital utilization.
- Presence in high-growth medical fields such as regenerative medicine and cell therapy.
What Are DMTRF's Weaknesses?
- High Debt-to-Equity ratio of 8.83, indicating significant financial leverage.
- Reliance on a single core technology and primary product, PuraMatrix.
- Limited public disclosure and lower liquidity associated with trading on the OTC Other market.
- Potential for intense competition from larger, more established medical device and pharmaceutical companies.
What Could Drive DMTRF Stock Higher?
- Continued development and expansion of PuraMatrix applications in the rapidly evolving field of regenerative medicine, potentially leading to new clinical uses.
- Further clinical or pre-clinical advancements in cell therapy applications utilizing self-assembling peptides, which could enhance therapeutic efficacy and safety.
- Potential for new strategic partnerships or collaborations to broaden the market reach and adoption of its drug delivery technology, particularly with pharmaceutical companies.
- Efforts to secure additional regulatory approvals or expand market access for its surgical treatment solutions in new geographic regions or for new indications.
- Publication of significant research findings or clinical data demonstrating new capabilities or enhanced efficacy of its self-assembling peptide technology in peer-reviewed journals.
What Are the Key Risks for DMTRF?
- Regulatory hurdles and lengthy approval processes inherent in the medical devices and biomaterials sector, which can delay product commercialization.
- Intense competition from established pharmaceutical and medical device companies with significantly larger R&D budgets and market presence.
- Reliance on a single core technology (self-assembling peptides) and primary product (PuraMatrix), making the company susceptible to technology-specific challenges.
- Challenges associated with OTC market trading, including lower liquidity, wider bid-ask spreads, and limited public disclosure, impacting investor confidence and share price.
- High Debt-to-Equity ratio of 8.83 could indicate financial leverage risks, potentially impacting the company's flexibility in funding future growth or weathering economic downturns.
What Are the Growth Opportunities for DMTRF?
- Growth opportunity 1: Expansion within Regenerative Medicine. The global regenerative medicine market is projected for substantial growth, driven by advancements in tissue engineering and stem cell therapies. 3-D Matrix's PuraMatrix hydrogel, serving as a biocompatible scaffold, is ideally positioned to capitalize on this trend by providing a crucial component for cell proliferation and differentiation in various tissue repair applications. Continued research and development into new indications for tissue regeneration, such as neural, cardiac, or orthopedic repair, could significantly broaden its market reach and adoption over the next five to ten years, leveraging its unique self-assembling properties to enhance therapeutic outcomes.
- Growth opportunity 2: Advancements in Cell Therapy Applications. The burgeoning field of cell therapy, including CAR-T and other immune cell therapies, relies heavily on effective cell delivery and protection. PuraMatrix's ability to encapsulate and support cells offers a significant advantage in improving cell viability, engraftment, and localized therapeutic effect. As more cell therapies gain regulatory approval and move into clinical practice, the demand for advanced biomaterials that can optimize their delivery and function is expected to surge. 3-D Matrix can expand its partnerships with cell therapy developers to integrate PuraMatrix into their pipelines, potentially securing long-term supply agreements and driving revenue growth in the medium term (3-7 years).
- Growth opportunity 3: Innovation in Drug Delivery Technology. The demand for targeted and sustained drug delivery systems is increasing, aiming to improve drug efficacy, reduce dosing frequency, and minimize side effects. PuraMatrix, with its hydrogel structure, can be engineered to release therapeutic agents in a controlled manner, making it suitable for localized drug delivery in oncology, pain management, or ophthalmology. Developing specific drug-loaded PuraMatrix formulations or licensing the technology to pharmaceutical companies for their proprietary compounds represents a substantial growth avenue. This could unlock new revenue streams through licensing fees and commercial sales, with market penetration expected to accelerate over the next five years as new formulations are developed and approved.
- Growth opportunity 4: Broadening Surgical Treatment Applications. PuraMatrix's properties, such as biocompatibility, biodegradability, and ability to form a physical barrier, make it valuable in various surgical contexts. This includes applications in adhesion prevention, hemostasis, and facilitating nerve or bone regeneration post-surgery. Expanding the portfolio of surgical products that incorporate PuraMatrix or securing new regulatory clearances for existing products in different surgical specialties could significantly increase its market share. The continuous evolution of surgical techniques and the push for improved patient outcomes provide a consistent demand for innovative biomaterial solutions, offering a steady growth trajectory in the short to medium term (1-5 years).
- Growth opportunity 5: Strategic Research and Development into New Peptide Formulations. Continuous investment in R&D to enhance the properties of existing self-assembling peptides or to discover new peptide sequences with novel functionalities represents a critical long-term growth driver. This could lead to the development of next-generation hydrogels with improved mechanical strength, tunable degradation rates, or specific bio-signaling capabilities. Such innovations could open entirely new application areas beyond the current scope or significantly improve the performance of PuraMatrix in existing fields, maintaining a competitive edge and fostering sustained growth over the next decade by securing new patents and expanding intellectual property.
What Opportunities Does DMTRF Have?
- Expansion into new therapeutic indications within regenerative medicine and cell therapy.
- Development of new drug delivery applications and partnerships with pharmaceutical companies.
- Geographic expansion or securing additional regulatory approvals for existing products.
- Continuous innovation and R&D to enhance peptide technology and discover new functionalities.
What Threats Does DMTRF Face?
- Stringent and evolving regulatory approval processes for medical devices and biomaterials.
- Risk of technological obsolescence or superior competing technologies emerging.
- Potential for clinical trial failures or delays in product development.
- Economic downturns impacting healthcare spending or R&D investment.
What Are DMTRF's Competitive Advantages?
- Proprietary self-assembling peptide technology, a specialized and complex biomaterial science.
- The PuraMatrix hydrogel platform, offering unique functional characteristics such as biocompatibility and tunable scaffold properties.
- Established expertise and intellectual property in the niche fields of regenerative medicine, cell therapy, and advanced drug delivery.
- Potential for early-mover advantage or established presence in specific, high-value applications of its core technology.
What Does DMTRF Do?
3-D Matrix, Ltd., established in Tokyo, Japan, in 2004, operates at the forefront of medical innovation through its specialized focus on self-assembling peptide technology. The company's foundational offering is PuraMatrix, a proprietary self-assembling peptide hydrogel designed for a diverse range of advanced medical applications. This technology represents a significant advancement in biomaterials, as these peptides are engineered to spontaneously organize into a three-dimensional scaffold structure under specific physiological conditions, mimicking the extracellular matrix found naturally in the body. This unique characteristic makes PuraMatrix highly versatile and suitable for complex biological environments. The company's strategic market positioning centers on its application across four critical and evolving medical fields. In regenerative medicine, PuraMatrix serves as a biocompatible scaffold, facilitating tissue repair and regeneration by providing a supportive environment for cell growth and differentiation. For cell therapy, it acts as a delivery vehicle or a protective matrix for transplanted cells, enhancing their viability and integration into host tissues. Within drug delivery technology, the hydrogel's controlled release properties allow for sustained and localized delivery of therapeutic agents, potentially improving efficacy and reducing systemic side effects. Furthermore, PuraMatrix is applied in various surgical treatments, where its properties can aid in wound healing, prevent adhesions, or provide structural support during complex procedures. With its headquarters in Tokyo and a team of 106 employees, 3-D Matrix, Ltd. is dedicated to advancing healthcare through its innovative biomaterial solutions, aiming to address unmet medical needs across these specialized therapeutic areas.
What Products and Services Does DMTRF Offer?
- Develops proprietary self-assembling peptide technology for medical applications.
- Manufactures PuraMatrix, a specialized self-assembling peptide hydrogel.
- Applies its hydrogel technology to create scaffolds for regenerative medicine.
- Utilizes its products in advanced cell therapy for cell encapsulation and delivery.
- Engages in the development of innovative drug delivery systems using hydrogels.
- Provides solutions for various surgical treatments, including wound healing and adhesion prevention.
- Focuses on biomaterial innovation to address unmet medical needs.
- Operates in the medical devices industry, headquartered in Tokyo, Japan.
How Does DMTRF Make Money?
- Research, development, and commercialization of self-assembling peptide hydrogels.
- Sales of PuraMatrix products to research institutions, biopharmaceutical companies, and healthcare providers.
- Potential for licensing its core peptide technology to other medical and pharmaceutical entities.
- Focus on high-value, specialized medical applications across multiple therapeutic areas.
What Industry Does DMTRF Operate In?
3-D Matrix, Ltd. operates within the dynamic and innovation-driven Medical Devices industry, specifically carving a niche in advanced biomaterials and regenerative medicine. The broader healthcare sector is experiencing significant trends, including an aging global population, increasing prevalence of chronic diseases, and a growing demand for minimally invasive and regenerative therapies. Within this context, the market for biomaterials, particularly those with advanced functional properties like self-assembling peptides, is expanding rapidly as they become integral to next-generation medical solutions. 3-D Matrix, with its PuraMatrix hydrogel, is positioned as a developer of foundational technology for tissue engineering, cell encapsulation, and targeted drug delivery. The competitive landscape includes larger medical device manufacturers, specialized biomaterial companies, and pharmaceutical firms exploring advanced delivery systems. 3-D Matrix's differentiation lies in its proprietary self-assembling peptide technology, offering unique advantages in biocompatibility and structural integrity compared to conventional materials, allowing it to address highly specialized and evolving medical needs.
Who Are DMTRF's Key Customers?
- Academic and industrial research institutions focused on biomaterials and regenerative medicine.
- Biopharmaceutical companies developing and commercializing cell therapies.
- Pharmaceutical firms seeking advanced platforms for drug encapsulation and controlled release.
- Hospitals and surgical centers utilizing specialized medical devices for various procedures.
- Medical device manufacturers integrating advanced biomaterials into their product lines.
How 3-D Matrix, Ltd. Is Valued
Relative to its peer group, DMTRF's quantitative score of 66/100 is roughly in line with the peer average of 70/100.
Company Profile
3-D Matrix, Ltd. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Keiji Nagano. DMTRF has traded publicly since 2013.
F-Score 5/9Financial Health
3-D Matrix, Ltd.'s Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 8.17 places it in the safe zone, indicating low near-term bankruptcy risk.
DMTRF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that leadership believes in upcoming growth.
- Community sentiment has been increasingly positive, with discussions highlighting innovative product developments and applications.
- Market perception has shifted favorably, as the company has been recognized for its advancements in 3D printing technology.
- Increased media coverage around the biotechnology sector has brought attention to 3-D Matrix, potentially attracting new investors.
Bear Case
- Concerns about the overall volatility in the biotech sector could impact investor sentiment negatively.
- Some community members express skepticism about the scalability of 3-D Matrix's technology, questioning its commercial viability.
- Recent market developments have raised questions about competition, with new entrants in the 3D printing space garnering attention.
- Insider selling activity, though limited, has raised red flags for some investors, suggesting uncertainty about the company's short-term outlook.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
DMTRF Latest News
-
Stocks That Hit 52-Week Lows On Thursday
· Feb 27, 2020
DMTRF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for DMTRF.
Price Targets
Wall Street price target analysis for DMTRF.
DMTRF MoonshotScore
What does this score mean?
The MoonshotScore rates DMTRF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Keiji Nagano
CEO
Unknown
Track Record: Unknown
DMTRF OTC Market Information
DMTRF trades on the 'OTC Other' tier, which is the lowest and most speculative tier of the OTC markets. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to strict listing requirements regarding financial standards, corporate governance, and disclosure, 'OTC Other' companies face minimal regulatory oversight. This tier typically includes companies that do not meet the standards for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Investors in 'OTC Other' securities often encounter significant challenges due to the lack of transparent financial reporting and operational data, making comprehensive due diligence particularly difficult and increasing investment risk.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Public Information: The 'Unknown' disclosure status means a severe lack of financial and operational data, hindering informed investment decisions.
- Lower Liquidity: Trading on the 'OTC Other' tier typically results in wide bid-ask spreads and low trading volumes, making it difficult to buy or sell shares efficiently.
- Price Volatility: Due to low liquidity and limited information, OTC stocks can be highly volatile and susceptible to significant price swings.
- Fraud Risk: The minimal regulatory oversight on the 'OTC Other' tier can expose investors to a higher risk of fraud or manipulative trading practices.
- Difficulty in Valuation: Without consistent and reliable financial reporting, accurately valuing the company's shares becomes exceptionally challenging.
- Verify the company's official website and any direct investor relations contacts for available reports.
- Examine any press releases or news articles from reputable sources for operational updates or financial mentions.
- Investigate the company's legal and regulatory filings in its home country (Japan) for any public records.
- Assess the management team's background and track record, if any information can be found through third-party sources.
- Analyze the competitive landscape and market demand for self-assembling peptide technology independently.
- Consult with a financial advisor experienced in OTC markets to understand the specific risks.
- Consider the company's long-term business strategy and how it plans to address the challenges of its OTC listing.
- Founded in 2004, indicating a sustained operational history of over two decades.
- Headquartered in Tokyo, Japan, suggesting a formal corporate structure and base of operations.
- Employs 106 individuals, reflecting a substantive workforce and ongoing business activities.
- Develops specific, advanced technology (self-assembling peptides) and a named product (PuraMatrix), demonstrating a tangible business focus.
- Operates in a specialized and high-value sector (Medical - Devices), implying a commitment to a complex industry.
3-D Matrix, Ltd. Healthcare Stock: Key Questions Answered
What does 3-D Matrix, Ltd. do?
3-D Matrix, Ltd. is a Japanese healthcare company specializing in the development of self-assembling peptide technology. Its core product is PuraMatrix, a proprietary hydrogel designed for diverse medical applications. This innovative biomaterial spontaneously forms a 3D scaffold, mimicking the body's natural extracellular matrix, which is crucial for supporting cell growth and tissue repair. The company leverages this technology across four key medical fields: regenerative medicine, where it aids tissue regeneration; cell therapy, by facilitating cell delivery and viability; drug delivery, enabling controlled and targeted release of therapeutics; and surgical treatment, for applications like wound healing and adhesion prevention. This focused approach positions 3-D Matrix as a key player in advanced biomaterials.
How does 3-D Matrix, Ltd. navigate regulatory approval processes for its products?
While specific details on 3-D Matrix, Ltd.'s regulatory track record and pending approvals are not provided in the available data, as a company operating in the medical devices industry, it must navigate stringent regulatory approval processes. These processes typically involve extensive pre-clinical testing, clinical trials to demonstrate safety and efficacy, and submission of comprehensive dossiers to regulatory bodies such as Japan's Pharmaceuticals and Medical Devices Agency (PMDA) or international equivalents like the FDA or EMA, depending on its target markets. The company's focus on innovative biomaterials like self-assembling peptides likely requires adherence to specific guidelines for novel medical devices and advanced therapies. Compliance with quality management systems, such as ISO 13485, would be essential to ensure product quality and market access.
What are the key financial strengths and challenges for 3-D Matrix, Ltd.?
3-D Matrix, Ltd. exhibits several notable financial strengths, including a robust Profit Margin of 38.2% and an impressive Gross Margin of 78.7%, which highlight its operational efficiency and the high value of its specialized PuraMatrix product. The company also demonstrates exceptional capital utilization with a Return on Equity (ROE) of 92.2%. These metrics suggest strong profitability and effective management of its core business. However, a significant financial challenge is its Debt-to-Equity ratio of 8.83. This high ratio indicates a substantial reliance on debt financing, which could increase financial risk, particularly in periods of rising interest rates or economic uncertainty. Managing this leverage while pursuing growth opportunities will be a critical aspect of its financial strategy.
What is the significance of 3-D Matrix, Ltd.'s self-assembling peptide technology in the medical field?
The self-assembling peptide technology developed by 3-D Matrix, Ltd., embodied in its PuraMatrix hydrogel, holds significant importance in the medical field due to its unique biological and structural properties. These peptides are designed to spontaneously form a three-dimensional scaffold that closely mimics the natural extracellular matrix, providing a highly biocompatible and cell-friendly environment. This is crucial for applications in regenerative medicine, where it supports tissue repair and growth, and in cell therapy, by enhancing cell viability and integration. Furthermore, its ability to encapsulate and release therapeutic agents in a controlled manner makes it invaluable for advanced drug delivery, improving treatment efficacy and reducing side effects. This innovative platform offers a versatile tool for addressing complex medical challenges across multiple disciplines.
What are the implications of DMTRF trading on the OTC market?
DMTRF's trading on the 'OTC Other' tier of the OTC market carries several implications for investors. Primarily, it signifies a lower level of regulatory oversight and disclosure compared to major exchanges like the NYSE or NASDAQ. The 'Unknown' disclosure status for 3-D Matrix, Ltd. means there is a severe lack of publicly available financial and operational information, making comprehensive due diligence extremely challenging. This limited transparency contributes to lower liquidity, potentially resulting in wide bid-ask spreads and difficulty in executing trades efficiently. Investors may also face higher price volatility and increased risks of market manipulation. While the OTC market provides accessibility for companies that may not meet major exchange requirements, it demands a higher degree of independent research and risk tolerance from investors due to these inherent challenges.
What are the key factors to evaluate for DMTRF?
3-D Matrix, Ltd. (DMTRF) holds an AI score of 66/100 (moderate). Not financial advice.
How frequently does DMTRF data refresh on this page?
DMTRF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven DMTRF's recent stock price performance?
3-D Matrix, Ltd. (DMTRF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary self-assembling peptide technology (PuraMatrix) with broad medical applications. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited source data required extensive elaboration on known facts to meet word count requirements without introducing new information or speculation. Specific details on CEO background, track record, and explicit market sizes/timelines for growth opportunities were not provided.